 |
Case Series
Three cases of neuropsychiatric systemic lupus erythematosus treated with telitacicept
1 Department of Rheumatology and Immunology, Clinical Medical College, The Affiliated Hospital of Southwest Medical University, Luzhou, China
2 Department of Rheumatology and Immunology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
Address correspondence to:
Xixi Chen
Li Long, No. 32, West Section 2, 1st Ring Road, Qingyang District, Chengdu, Sichuan,
China
Message to Corresponding Author
Article ID: 100085Z09WZ2026
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Zhang W, Zheng Y, Chen X, Long L. Three cases of neuropsychiatric systemic lupus erythematosus treated with telitacicept. J Case Rep Images Med 2026;11(1):5–11.ABSTRACT
Introduction: Neuropsychiatric lupus (NPSLE) is a serious complication of systemic lupus erythematosus (SLE). Telitacicept, a novel B-cell-targeting biologic, has been approved in China for SLE treatment; however, evidence supporting its use specifically in NPSLE remains limited. Evidence for telitacicept in NPSLE is currently limited to individual case reports. As one of the first case series to address this issue, we summarize the treatment courses of these patients to provide stronger evidence for clinical practice.
Case Series: This retrospective case series describes three patients with NPSLE who had an insufficient response to conventional immunosuppressants. Follow-up periods ranged from 7 to 36 months. After adding combination therapy with telitacicept (160 mg weekly), all patients exhibited significant improvement in neuropsychiatric symptoms, a marked reduction in disease activity score, and amelioration in relevant immunological and imaging parameters. No serious adverse events were observed during follow-up.
Conclusion: Telitacicep may offer therapeutic benefit in managing NPSLE, particularly in cases presenting with predominant psychiatric manifestations.
Keywords: Biologics, Neuropsychiatric systemic lupus erythematosus, Telitacicept, Treatment
SUPPORTING INFORMATION
Author Contributions
Wei Zhang - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Yawen Zheng - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Xixi Chen - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Li Long - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2026 Wei Zhang et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
